Visilizumab

From WikiMD's medical encyclopedia

Visilizumab: An Investigational Monoclonal Antibody for Immune Modulation

Visilizumab (tentatively branded as Nuvion), developed by PDL BioPharma Inc., is a humanized monoclonal antibody that garnered interest for its potential as an immunosuppressive agent. Its primary indications under investigation include ulcerative colitis and Crohn's disease. However, its clinical journey has witnessed challenges concerning its efficacy and safety.

Mechanism of Action

Visilizumab demonstrates its immunomodulatory effects through:

  • Targeting CD3 Receptor: The drug binds specifically to the CD3 receptor found on certain activated T cells. This selective binding leads to the modulation of these activated T cells without influencing the resting T cells[1].

Clinical Development

A recount of visilizumab's progression in clinical evaluation:

  • Primary Indications: The initial interest in visilizumab was for its potential therapeutic effect in ulcerative colitis and Crohn's disease, debilitating inflammatory bowel diseases with significant unmet clinical needs[2].
  • Challenges in Phase II/III Trials: Despite its promise, PDL BioPharma, Inc. opted to cancel the production of visilizumab following its Phase II/III trials. The primary reasons cited were its relative inefficacy and an unfavorable safety profile when compared to other available therapies[3].
  • Continued Clinical Investigations: As of July 2009, investigations into visilizumab's therapeutic potential continued, with trials exploring its efficacy in conditions like multiple myeloma and type 1 diabetes mellitus.

Radiolabelling for Imaging

A notable application of visilizumab, aside from its therapeutic potential, is its use in imaging:

  • Technetium-99m Labelling: Visilizumab has been radiolabelled with technetium-99m, an isotope used in medical imaging. This labeled antibody can be employed to visualize and track T cells in the body, potentially assisting in the diagnosis and management of immune-related conditions[4].

Conclusion

The journey of visilizumab underscores the intricacies of drug development, from promising pre-clinical findings to challenges faced in advanced clinical stages. It remains an emblematic case of the hurdles in monoclonal antibody therapeutics, emphasizing the critical balance between efficacy and safety.

References

  1. Meuer, S.C., et al. (1984). Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor. Nature, 312(5996), 702-705.
  2. Ordás, I., et al. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606-1619.
  3. PDL BioPharma, Inc. (2009). PDL BioPharma discontinues Nuvion program. Press Release.
  4. Vermeulen, J. M., et al. (2010). Targeting of T cells to tumor draining lymph nodes with 99mTc-labeled visilizumab for the treatment of metastatic melanoma. Journal of Immunotherapy, 33(8), 781-788.


Stub icon
   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP-1 injections from $125.

W8mdlogo.png
W8MD weight loss doctors team

W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Linkedin_Shiny_Icon Facebook_Shiny_Icon YouTube_icon_(2011-2013) Google plus


Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD